1 / 17

Dose Content Uniformity for Aerosol Products

Dose Content Uniformity for Aerosol Products. Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD. Two Guidances. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - CMC Documentation (Draft, October 1998)

MikeCarlo
Download Presentation

Dose Content Uniformity for Aerosol Products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dose Content Uniformityfor Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD

  2. Two Guidances • Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - CMC Documentation (Draft, October 1998) • Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - CMC Documentation (Final, July 2002)

  3. The DCU and SCU Issue • DCU (dose content uniformity) • SCU (spray content uniformity) • Uniformity of metered doses from an MDI, DPI or nasal spray • within a container for multiple dose products • among containers • among batches

  4. Present DCU and SCU Tests • Nonparametric (with a parametric element) • Single dose and multi-dose products • At tier 1 • NMT 1 of 10 containers outside of 80 - 120% of label claim (LC) • 0 outside 75 - 125% of LC • Mean of 10 not outside 85 - 115% LC

  5. Present DCU and SCU Tests:DCU Through Container Lifefor Multi-dose Products • MDIs • DCU measured at B, M and E lifestages • for each of three containers • NMT 1 of 9 determinations outside 80 - 120% of LC • 0 outside 75 - 125% of LC • means at each of B, M and E not outside 85 - 115% of LC

  6. Present DCU and SCU Tests:DCU Through Container Lifefor Multi-dose Products • DPIs (device-metered) • Same as for MDIs • Nasal sprays • Similar to MDIs, except 10 determinations at B and 10 at E

  7. A Parametric Tolerance Interval Approach General form of the criterion: Y  kS where: Y = absolute value (LC - sample mean) k = a tolerance interval constant s = sample std dev Per discussion with Dr. Walter Hauck

  8. A Parametric Tolerance Interval • Intended to control ranges of specified coverage, e.g., • 85% of the doses within • 75 - 125% of LC at • 95% confidence • We therefore specify • min proportion of the batch that should fall within the limits (coverage) • acceptable tolerance limits (target interval) • degree of confidence Per discussion with Dr. Walter Hauck

  9. Development Of ParametricTolerance Interval Approaches • Official in Japanese Pharmacopoeia (JP, 1996) • Pharmacopoeial Discussion Group • European Pharmacopoeia, JP, and USP • Statistics Working Group of PhRMA • ICH/PDG Task Force

  10. Development Of Parametric Tolerance Interval Approaches, cont. • Content Uniformity and Dose Uniformity: Current Approaches, Statistical Analyses, and Presentation of an Alternative Approach, with Special Reference to Oral Inhalation and Nasal Drug Products • RL Williams et al, Pharm Res, 2002;19:359-66 • A Parametric Tolerance Interval Test for Improved Control of Delivered Dose Uniformity of Orally Inhaled and Nasal Drug Products • IPAC-RS, 15 November 2001

  11. OPS Issues • Definition of limiting quality • Essential to an acceptable DDU test • 85% of doses in the batch within 75 - 125% of label claim? • 85% of doses within 80 - 120% of label claim? • 90% of doses within 75 - 125% of label claim? • 90% of doses within 80 - 120% of label claim? • other options?

  12. OPS Issues • Robustness of the test • for non-normally distributed data • e.g., short-tailed distribution • properties of the test when the batch is at or below the IPAC-proposed limiting quality (e.g., 85% coverage)

  13. OPS Issues • Impact of eliminating the zero tolerance criterion (ZTC) • IPAC-RS claims that ZTC increases producer risk with little improvement in consumer protection • value for skewed data

  14. OPS Issues •  level (less than or equal to 0.05) • Estimated consumer risk of IPAC-RS proposal exceeds 5% • Approaches to assuring  0.05

  15. Question # 1 for ACPS • Does ACPS agree that a parametrictolerance interval test is conceptually acceptable as a replacement for the agency’s nonparametric (with certain parametric elements) DCU and DCU through container life tests for OINDPs?

  16. Question # 2 for ACPS • Does ACPS feel that DCU quality standards should provide assurance that batch failure rates do not exceed some specified level, e.g., 10%?

  17. Acknowledgments • Ajaz Hussain (FDA) • Guirag Poochikian (FDA) • Don Schuirmann (FDA • Meiyu Shen (FDA) • Yi Tsong (FDA) • Walter Hauck (Thomas Jefferson University) • Roger Williams (USP)

More Related